Diagnostic agent developer Lantheus Medical Imaging said on March 21 that it is taking steps to cut expenses, such as reducing internal R&D resources and seeking a partner to assist in the final development of one of its most promising PET radiopharmaceuticals.
Lantheus is currently completing the first of two phase III clinical trials for flurpiridaz F-18, a PET radiopharmaceutical for detecting coronary artery disease. The firm said it will seek a strategic partner to support the balance of the phase III program, as well as to assist in commercialization of the agent.
Lantheus will also reduce R&D spending, beginning immediately. The company said the moves will help it focus on its portfolio of commercially available products.
